On February 10, 2022 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reported that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 23rd, at 4:30 p.m. ET to discuss fourth quarter and full year 2021 financial results and provide a general business update (Press release, BioMarin, FEB 10, 2022, View Source,-February-23-at-4-30pm-ET [SID1234607967]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioMarin to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on Wed., February 23 at 4:30pm ET

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com. A replay of the call will be archived on the site for one week following the call.

On February 10, 2022 Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported that it will report financial results for its fourth quarter of fiscal 2021 ended November 30, 2021 as well as for its full fiscal year 2021 on Thursday, February 24, 2022 (Press release, Theratechnologies, FEB 10, 2022, View Source [SID1234607983]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A conference call will be held on February 24, 2022 at 8:30 a.m. (ET) to discuss the results and recent business updates. The call will be hosted by Paul Lévesque, President and Chief Executive Officer. Mr. Lévesque and other members of the management team will be available to answer questions from participants following prepared remarks.

The conference call can be accessed by dialing 1-844-400-1697 (toll free) or 1-703-736-7400 (International). The conference call will also be accessible via webcast at View Source An audio replay of the conference call will be available on the same day starting at 11:30 a.m. (ET) until March 3, 2022 by dialing 1-855-859-2056 (North America) or 1-404-537-3406 (International) and by entering the access code: 8659715. An archived webcast will also be available on the Company’s Investor Relations website under ‘Past Events’.

On February 10, 2022 SystImmune, Inc. a clinical-stage company developing innovative cancer therapeutics, including novel bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs), reported the appointment of Martin Sebastian Olivo, M.D. as Chief Medical Officer, effective on February 7, 2022 (Press release, SystImmune, FEB 10, 2022, View Source [SID1234607999]). Dr. Olivo joined SystImmune, Inc. from Protara Therapeutics, Inc. where he served as the Chief Medical Officer and led the advancement of the early-stage clinical effort in the area of non-muscle invasive bladder cancer. Dr. Olivo brings decades of experience in oncology clinical research and global drug development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"It is our honor to welcome Dr. Olivo to our team," said Dr. Yi Zhu, the Chief Executive Officer of SystImmune, Inc. "As the leader of the clinical development arm of SystImmune, Inc. Dr. Olivo will be instrumental in advancing and expanding the global clinical impact of our pipeline. With several ongoing Phase II & Phase I trials, there is a huge opportunity for Dr. Olivo to leverage his strengths in product development among several oncology indications."

"I feel fortunate to join SystImmune, Inc. at this stage," said Dr. Olivo. "SystImmune, Inc. has the potential to play a meaningful role in the treatment of difficult to treat cancers and I’m looking forward to working with the many talented individuals to advance transformative therapies for people with cancer."

Before assuming his most recent role at Protara Therapeutics, Inc., Dr. Olivo led late-stage clinical efforts in breast cancer therapeutics development as the Vice President of Clinical Development at Gilead Sciences, Inc., (formerly Immunomedics, Inc.) from Aug 2018 to April 2021. Earlier, Dr. Olivo served as the Global Clinical lead at Daiichi Sankyo Cancer Enterprise, where he established a comprehensive clinical development plan to advance ADC therapeutics for IND filing in the US. Prior to that, Dr. Olivo served several roles with increasing responsibilities in the oncology group at Eisai Inc.

Dr. Olivo earned his M.D. from the University of Buenos Aires and his M.S. in Clinical and Pharmacological Research from Austral University in Buenos Aires. He also completed advanced training as a Clinical Oncologist at the University of Salvador. Dr. Olivo then held various academic and clinical positions at the School of Medicine at the University of Buenos Aires, Hospital "Dr. Enrique Tornú" and the National Cancer Institute of Canada Clinical Trials Group.

On February 10, 2022 Scandion Oncology (Scandion) reported that it will publish its yearend 2021 report on Thursday, February 17, 2022 before 08:00 CET (Press release, Scandion Oncology, FEB 10, 2022, View Source;2022,c3500878 [SID1234607950]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Scandion Oncology’s executive management will host a webcast and conference call the same day at 08:30 CET presenting the results and a company update.

At the end of the presentation there will be a Q&A session.

Webcast replay will be available at www.scandiononcology.com in the Investors section and at www.financialhearings.com

The information was provided by the contact person above for publication on February 10, 2022, at 08.30 CET.

On February 10, 2022 SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, and Telix Pharmaceuticals LTD (Telix), a biopharmaceutical company headquartered in Australia, reported the signing of a clinical supply agreement that provides Telix with SHINE’s non-carrier-added (n.c.a.) lutetium-177 (Lu-177) for use in the clinical development of potential new therapeutics to treat prostate and kidney cancer (Press release, Shine Medical Technologies, FEB 10, 2022, View Source [SID1234607968]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SHINE will immediately commence supply of n.c.a. Lu-177 for use in clinical trials of Telix’s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer), with particular focus on the US market.

"There continues to be a growing, critical need for more effective treatment of metastatic or late-stage cancers," said Greg Piefer, SHINE’s founder and CEO. "Our exciting partnership with Telix allows us to bring hope to these patients as we continue to help deliver Lu-177 for highly precise treatments that produce little damage in the tissue around treatment sites."

SHINE’s Therapeutics division produces n.c.a. Lu-177, a low-energy beta-particle emitter, which can be paired with a targeting molecule (such as an antibody or peptide) to directly target and irradiate cancer cells. Several Lu-177 therapies are currently being developed to treat various forms of cancer and may provide alternative treatment options for patients where other therapeutic solutions have proven insufficient.

Dr. Gabriel Liberatore, Telix Group Chief Operating Officer continued, "SHINE’s investment in high quality isotope production places them at the forefront of the radiopharmaceutical supply chain with particular strength in servicing the US market. The agreement with SHINE supports our goal to establish a global supply chain with the capacity and reliability to support an increasing level of clinical activity through Telix-sponsored and investigator-led studies and to scale-up to commercial stage."